Clinical Trials - September 14, 2022
Alligator Bioscience presents Phase 1b/2 data
Alligator Bioscience has announced a poster presentation on the OPTIMIZE-1 Phase 1b/2 trial of mitazalimab in combination with modified FOLFIRINOX in first-line metastatic pancreatic cancer with the company’s lead asset mitazalimab at the 2022 AACR Special Conference on Pancreatic Cancer, being held in Boston September 13-16. The presentation, entitled “Mitazalimab (CD40 agonist) in combination with […]
Clinical Trials - September 8, 2022
Dizlin Pharmaceuticals publishes data from pharmacokinetic study
The Gothenburg based company has announced that an article has been published in Neurology, from the American Academy of Neurology, describing data from the company’s IPO-001 pharmacokinetic cross-over study. In a pharmacokinetic cross-over study comprising 18 evaluable subjects with advanced Parkinson’s disease, levodopa/carbidopa solutions with a pH of 5.5 were produced by continuous buffering shortly […]
Clinical Trials - September 7, 2022
IRLAB’s partner initiates clinical studies
IRLAB Therapeutics have announced that its partner Ipsen has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan. These are standard clinical pharmacokinetic studies that will run in parallel to the Phase IIb study with mesdopetam that is currently being conducted by IRLAB with results anticipated around the end of the […]
Clinical Trials - September 6, 2022
BioInvent completes dose-escalation in Phase 1/2a trial
BioInvent International has announced the completion of the planned dose escalation part of its Phase 1/2a trial of the anti-TNFR2 drug candidate BI-1808. Given the positive safety and tolerability profile observed so far, a higher dose of BI-1808 as single agent will be tested to explore the effect of higher exposure, states the company. In […]
Clinical Trials - September 5, 2022
Peer-reviewed research supports TikoMed’s ILB’s mode of action
New research shows that ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including Amyothrophic Lateral Sclerosis (ALS). TikoMed has announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the broad spectrum mechanism of action of TikoMed’s ILB neuroprotective drug platform. In […]
Clinical Trials - September 2, 2022
EpiEndo starts clinical trial with its lead molecule
EpiEndo Pharmaceuticals has received regulatory and ethics approval to commence a Lipopolysaccharide (LPS) challenge clinical trial with its lead molecule EP395. EP395 is an orally available macrolide or ‘Barriolide’ with reduced antimicrobial activity which aims to address the unmet medical need for a treatment for COPD (Chronic Obstructive Pulmonary Disease). “Commencing this study is the […]
